Calorie restriction mimetics: Can you have your cake and eat it, too?

Ageing Research Reviews

Volumn 20, Issue , 2015, Pages 46-62

  Ingram, Donald K ^a   Roth, George S ^b  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b GeroScience Inc   (United States)

Author keywords

Aging; Diet restriction; Insulin; Metabolism; MTOR; Sirtuin

Indexed keywords

3 BROMOPYRUVATE; ACARBOSE; AGENTS AFFECTING METABOLISM; CALORIE RESTRICTION MIMETIC; CARBOHYDRATE; CHITOSAN; DEOXYGLUCOSE; FAT; GLUCOSAMINE; INSULIN; INSULIN RECEPTOR; IODOACETIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; MANNOHEPTULOSE; MANNOSE OLIGOSACCHARIDE; METFORMIN; NICOTINAMIDE; OXALOACETIC ACID; POLYAMINE; RESVERATROL; SIRTUIN; SOMATOMEDIN C; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; ANTIMETABOLITE;

AGING; BARIATRIC SURGERY; CALORIC INTAKE; CALORIC RESTRICTION; CARDIOTOXICITY; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DIET SUPPLEMENTATION; DIGESTION; DIGESTIVE SYSTEM; ENERGY YIELD; ENZYME INHIBITION; FAT INTAKE; FOOD INTAKE; GERONTOLOGY; GLYCOLYSIS; HUMAN; INTESTINE ABSORPTION; LONGEVITY; META ANALYSIS (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPIC VARIATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECTS; GASTROINTESTINAL ABSORPTION; PHYSIOLOGY; PROCEDURES;

RATTUS;

AGING; ANIMALS; ANTIMETABOLITES; BARIATRIC SURGERY; CALORIC RESTRICTION; GASTROINTESTINAL ABSORPTION; GLYCOLYSIS; HUMANS; LONGEVITY;

EID: 84923349090     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2014.11.005     Document Type: Review

References (261)

1. Ali A.A., Poortvliet E., Strömberg R., Yngve A. Polyamines in foods: development of a food database. Food Nutr. Res. 2011, 55:5572.
2. Aljada A., Dong L., Mousa S.A. Sirtuin-targeting drugs: mechanisms of action and potential therapeutic applications. Curr. Opin. Investig. Drugs 2010, 11:1158-1168.
3. Anandan R., Ganesan B., Obulesu T., Mathew S., Asha K.K., Lakshmanan P.T., Zynudheen A.A. Antiaging effect of dietary chitosan supplementation on glutathione-dependent antioxidant system in young and aged rats. Cell Stress Chaperones 2013, 18:121-125.
4. Anisimov V.N. Insulin/IGF-1 signaling pathway driving aging and cancer as a target for pharmacological intervention. Exp. Gerontol. 2003, 38:1041-1049.
5. Anisimov V.N. Metformin: do we finally have an anti-aging drug?. Cell Cycle 2013, 15:3483-3489.
6. Anisimov V.N., Berstein L.M., Egormin P.A., Piskunova T.S., Popovich I.G., Zabezhinski M.A., Kovalenko I.G., Poroshina T.E., Semenchenko A.V., Provinciali M., Re F., Franceschi C. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp. Gerontol. 2005, 40:685-693.
7. Anisimov V.N., Berstein L.M., Egormin P.A., Piskunova T.S., Popovich I.G., Zabezhinski M.A., Tyndyk M.L., Yurova M.V., Kovalenko I.G., Poroshina T.E., Semenchenko A.V. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle 2008, 7:2769-2773.
8. Anisimov V.N., Egormin P.A., Piskunova T.S., Popovich I.G., Tyndyk M.L., Yurova M.N., Zabezhinski M.A., Anikin I.V., Karkach A.S., Romanyukha A.A. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 2010, 9:188-197.
9. Anisimov V.N., Zabezhinski M.A., Popovich I.G., Piskunova T.S., Semenchenko A.V., Tyndyk M.L., Yurova M.N., Antoch M.P., Blagosklonny M.V. Rapamycin extends maximal lifespan in cancer-prone mice. Am. J. Pathol. 2010, 176:2092-2097.
10. Anisimov V.N., Zabezhinski M.A., Popovich I.G., Piskunova T.S., Semenchenko A.V., Tyndyk M.L., Yurova M.N., Rosenfeld S.V., Blagosklonny M.V. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle 2011, 10:4230-4236.
11. Asano I., Umemura M., Fujii S., Hoshino H., Iino H. Effects of mannooligosaccharides from coffee mannan on fecal microflora and defecation in healthy volunteers. Food Sci. Technol. Res. 2004, 10:93-97.
12. Bailey C.J., Turner R.C. Metformin. N. Engl. J. Med. 1996, 334:574-579.
13. Balfour J.A., McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993, 46:1025-1054.
14. Baker W.L., Tercius A., Anglade M., White C.M., Coleman C.I. A meta-analysis evaluating the impact of chitosan on serum lipids in hypercholesterolemic patients. Ann. Nutr. Metab. 2009, 55:368-374. (Nov 13, Epub).
15. Baksi A., Kraydashenko O., Zalevkaya A., Stets R., Elliott P., Haddad J., Hoffmann E., Vlasuk G.P., Jacobson E.W. A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes. J. Clin. Pharmacol. 2014, 10.1111/bcp.12327.
16. Barger J.L., Kayo T., Vann J.M., Arias E.B., Wang J., Hacker T.A., Wang Y., Raederstorff D., Morrow J.D., Leeuwenburgh C., Allison D.B., Saupe K.W., Cartee G.D., Weindruch R., Prolla T.A. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS ONE 2008, 3:e2264.
17. Bartke A. Insulin and aging. Cell Cycle 2008, 7:3338-3344.
18. Bass T.M., Weinkove D., Hourthoofd K., Gems D., Partridge L. Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans. Mech. Ageing Dev. 2007, 128:546-552.
19. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., Pistell P.J., Poosala S., Becker K.G., Boss O., Gwinn D., Wang M., Ramaswamy S., Fishbein K.W., Spencer R.G., Lakatta E.G., Le Couteur D., Shaw R.J., Navas P., Puigserver P., Ingram D.K., de Cabo R., Sinclair D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
20. Baur J.A. Resveratrol, sirtuins, and the promise of a DR mimetic. Mech. Ageing Dev. 2010, 131:261-269.
21. Bause AS1, Haigis M.C. SIRT3 regulation of mitochondrial oxidative stress. Exp. Gerontol. 2013, 48:634-639.
22. Bellizzi D., Rose G., Cavalcante P., Covello G., Dato S., De Rango F., Greco V., Maggiolini M., Feraco E., Mari V., Franceschi C., Passarino G., De Benedictis G. A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages. Genomics 2005, 85:258-263.
23. Ben Sahra I., Le Marchand-Brustel Y., Tanti J.F., Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug?. Mol. Cancer Ther. 2010, 9:1092-1099.
24. Berthoud H.R., Shin A.C., Zheng H. Obesity surgery and gut-brain communication. Physiol. Behav. 2011, 105:106-119.
25. Betz C., Stracka D., Prescianotto-Baschong C., Frieden M., Demaurex N., Hall M.N. mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:12526-12534.
26. Bhatt J.K., Thomas S., Nanjan M.J. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr. Res. 2012, 32:537-541.
27. Bishop N.A., Guarente L. Genetic links between diet and lifespan: shared mechanisms from yeast to humans. Nat. Rev. Genet. 2007, 8:835-844.
28. Blagosklonny M.V. Calorie restriction: decelerating mTOR-driven aging from cells to organisms (including humans). Cell Cycle 2010, 15:683-688.
29. Boussageon R1, Supper I., Bejan-Angoulvant T., Kellou N., Cucherat M., Boissel J.P., Kassai B., Moreau A., Gueyffier F., Cornu C. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med. 2012, 9(4):e1001204. 10.1371/journal.pmed.1001204.
30. Bradley D., Magkos F., Klein S. Effects of bariatric surgery on glucose homeostasis and type 2 diabetes. Gastroenterology 2012, 143:897-912.
31. Brand-Miller J.C., Atkinson F.S., Gahler R.J., Kacinik V., Lyon M.R., Wood S. Effects of PGX, a novel functional fibre, on acute and delayed postprandial glycaemia. Eur. J. Clin. Nutr. 2010, 64:1488-1493.
32. Cabreiro F1, Au C., Leung K.Y., Vergara-Irigaray N., Cochemé H.M., Noori T., Weinkove D., Schuster E., Greene N.D., Gems D. Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell 2013, 28:228-239.
33. Caccamo A., Magrì A., Medina D.X., Wisely E.V., López-Aranda M.F., Silva A.J., Oddo S. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. Aging Cell 2013, 12:370-380.
34. Caccamo A., Majumder S., Richardson A., Strong R., Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J. Biol. Chem. 2010, 285:13107-13120.
35. Calabrese E.J. Hormesis: from marginalization to mainstream: a case for hormesis as the default dose-response model in risk assessment. Toxicol. Appl. Pharmacol. 2004, 197:125-136.
36. Campos F., Sobrino T., Ramos-Cabrer P., Argibay B., Agulla J., Pérez-Mato M., Rodríguez-González R., Brea D., Castillo J. Neuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: an experimental study. J. Cereb. Blood Flow Metab. 2011, 31:1378-1386.
37. Carabin I.G., Lyon M.R., Wood S., Pelletier X., Donazzolo Y., Burdock G.A. Supplementation of the diet with the functional fiber PolyGlycoplex is well tolerated by healthy subjects in a clinical trial. Nutr. J. 2009, 8:9.
38. Caramés B., Kiosses W.B., Akasaki Y., Brinson D.C., Eap W., Koziol J., Lotz M.K. Glucosamine activates autophagy in vitro and in vivo. Arthritis Rheum. 2013, 65:1843-1852.
39. Cash A. Oxaloacetic acid supplementation as a mimic of calorie restriction. Open Longev. Sci. 2009, 3:22-27.
40. Chang J.M., Chung J.W., Jae H.J., Eh H., Son K.R., Lee K.C., Park J.H. Local toxicity of hepatic arterial infusion of hexokinase II inhibitor, 3-bromopyruvate: in vivo investigation in normal rabbit model. Acad. Radiol. 2007, 14:85-92.
41. Chang G.R., Wu Y.Y., Chiu Y.S., Chen W.Y., Liao J.W., Hsu H.M., Chao T.H., Hung S.W., Mao F.C. Long-term administration of rapamycin reduces adiposity, but impairs glucose tolerance in high-fat diet-fed KK/HlJ mice. Basic Clin. Pharmacol. Toxicol. 2009, 105:188-198.
42. Chao J., Yu M.S., Ho Y.S., Wang M., Chang R.C. Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity. Free Radic. Biol. Med. 2008, 45:1019-1026.
43. Chen D., Guarente L. SIR2: a potential target for calorie restriction mimetics. Trends Mol. Med. 2007, 13:64-71.
44. Chen H.L., Cheng H.C., Wu W.T., Liu Y.J., Liu S.Y. Supplementation of konjac glucomannan into a low-fiber Chinese diet promoted bowel movement and improved colonic ecology in constipated adults: a placebo-controlled, diet-controlled trial. J. Am. Coll. Nutr. 2008, 27:102-108.
45. Chung K.W., Kim D.H., Park M.H., Choi Y.J., Kim N.D., Lee J., Yu B.P., Chung H.Y. Recent advances in calorie restriction research on aging. Exp. Gerontol. 2013, 48:1049-1053.
46. Ciuffreda L., Di Sanza C., Incani U.C., Milella M. The mTOR pathway: a new target in cancer therapy. Curr. Cancer Drug Targets 2010, 10:484-495.
47. Collier C.A., Bruce C.R., Smith A.C., Lopaschuk G., Dyck D.J. Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 2006, 291:E182-E189.
48. Colman R.J., Beasley T.M., Kemnitz J.W., Johnson S.C., Weindruch R., Anderson R.M. Caloric restriction reduces age-related and all-cause mortality in rhesus monkeys. Nat. Commun. 2014, 1(5):3557.
49. Colman R.J., Anderson R.M., Johnson S.C., Kastman E.K., Kosmatka K.J., Beasley T.M., Allison D.B., Cruzen C., Simmons H.A., Kemnitz J.W., Weindruch R. Science 2009, 325:201-204.
50. Das D.K., Mukherjee S., Ray D. Resveratrol and red wine, healthy heart and longevity. Heart Fail. Rev. 2010, 15:467-477.
51. Davenport G., Massimino S., Hayek M., Burr J., Michael Ceddia M., Yeh C.-H., Roth G., Ingram D. Biological activity of avocado-derived mannoheptulose in dogs. Exp. Biol. 2010, (Abstract 725.4).
52. De Haes W., Frooninckx L., Van Assche R., Smolders A., Depuydt G., Billen J., Braeckman B.P., Schoofs L., Temmerman L. Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E2501-E2509.
53. Derosa G., Maffioli P. Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review. Clin. Ther. 2012, 34:1221-1236.
54. Dhahbi J.M., Mote P.L., Fahy G.M., Spindler S.R. Identification of potential caloric restriction mimetics by microarray profiling. Physiol. Genomics 2005, 23:343-350.
55. Dirks A.J., Leeuwenburgh C. Caloric restriction in humans: potential pitfalls and health concerns. Mech. Ageing Dev. 2006, 127:1-7.
56. Duan W., Mattson M.P. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. Res. 1999, 57:195-206.
57. Eisenberg T., Knauer H., Schauer A., Büttner S., Ruckenstuhl C., Carmona-Gutierrez D., Ring J., Schroeder S., Magnes C., Antonacci L., Fussi H., Deszcz L., Hartl R., Schraml E., Criollo A., Megalou E., Weiskopf D., Laun P., Heeren G., Breitenbach M., Grubeck-Loebenstein B., Herker E., Fahrenkrog B., Fröhlich K.U., Sinner F., Tavernarakis N., Minois N., Kroemer G., Madeo F. Induction of autophagy by spermidine promotes longevity. Nat. Cell Biol. 2009, 11:305-314.
58. Eurich D.T., Majumdar S.R., McAlister F.A., Tsuyuki R.T., Johnson J.A. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005, 28:2345-2351.
59. Fang Y., Vilella-Bach M., Bachmann R., Flanigan A., Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 2001, 294:1942-1945.
60. Fang Y., Westbrook R., Hill C., Boparai R.K., Arum O., Spong A., Wang F., Javors M.A., Chen J., Sun L.Y., Bartke A. Duration of rapamycin treatment has differential effects on metabolism in mice. Cell Metab 2013, 217:456-462.
61. Feige J.N., Lagouge M., Canto C., Strehle A., Houten S.M., Milne J.C., Lambert P.D., Mataki C., Elliott P.J., Auwerx J. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab 2008, 8:347-358.
62. Flynn J.M., O'Leary M.N., Zambataro C.A., Academia E.C., Presley M.P., Garrett B.J., Zykovich A., Mooney S.D., Strong R., Rosen C.J., Kapahi P., Nelson M.D., Kennedy B.K., Melov S. Late-life rapamycin treatment reverses age-related heart dysfunction. Aging Cell 2013, 12:851-862.
63. Fok W.C., Chen Y., Bokov A., Zhang Y., Salmon A.B., Diaz V., Javors M., Wood W.H., Zhang Y., Becker K.G., Pérez V.I., Richardson A. Mice fed rapamycin have an increase in lifespan associated with major changes in the liver transcriptome. PLOS ONE 2014, 9(1):e83988.
64. Fontana L., Partridge L., Longo V.D. Extending healthy life span-from yeast to humans. Science 2010, 328:321-326.
65. Foretz M., Hébrard S., Leclerc J., Zarrinpashneh E., Soty M., Mithieux G., Sakamoto K., Andreelli F., Viollet B. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 2010, 120:2355-2369.
66. Fraenkel M., Ketzinel-Gilad M., Ariav Y., Pappo O., Karaca M., Castel J., Berthault M.F., Magnan C., Cerasi E., Kaiser N., Leibowitz G. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008, 57:945-957.
67. Frantz S., Calvillo L., Tillmanns J., Elbing I., Dienesch C., Bischoff H., Ertl G., Bauersachs J. Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose. FASEB J. 2005, 19:591-593.
68. Frias M., Thoreen C., Jaffe J., Schroder W., Sculley T., Carr S., Sabatini D. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr. Biol. 2006, 16:1865-1870.
69. Froelich L., Ding A., Hoyer S. Holeboard maze-learning deficits and brain monoaminergic neurotransmitter concentrations in rats after intracerebroventricular injection of 3-bromopyruvate. Pharmacol. Biochem. Behav. 1995, 51:917-922.
70. Fuemayor L.D., Diaz S. The effect of feeding on the stereotyped behaviour induced by amphetamine and by apomorphine in the albino rat. Eur. J. Pharmacol. 1984, 99:153-158.
71. García-Caballero M., Valle M., Martínez-Moreno J.M., Miralles F., Toval J.A., Mata J.M., Osorio D., Mínguez A. Resolution of diabetes mellitus and metabolic syndrome in normal weight 24-29 BMI patients with one anastomosis gastric bypass. Nutr. Hosp. 2012, 27:623-631.
72. Giovannucci E., Harlan D.M., Archer M.C., Bergenstal R.M., Gapstur S.M., Habel L.A., Pollak M., Regensteiner J.G., Yee D. Diabetes and cancer: a consensus report. CA. Cancer J. Clin. 2010, 60:207-221.
73. Gomes GM1, Mello C.F., da Rosa M.M., Bochi G.V., Ferreira J., Barron S., Rubin M.A. Polyaminergic agents modulate contextual fear extinction in rats. Neurobiol. Learn. Mem. 2010, 93:589-595.
74. Gong B., Pan Y., Vempati P., Zhao W., Knable L., Ho L., Wang J., Sastre M., Ono K., Sauve A.A., Pasinetti G.M. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol. Aging 2013, 34:1581-1588.
75. Green K.N., Steffan J.S., Martinez-Coria H., Sun X., Schreiber S.S., Thompson L.M., LaFerla F.M. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J. Neurosci. 2008, 28:11500-11510.
76. Gridley D.S., Nutter R.L., Kettering J.D., Mantik D.W., Slater J.M. Mouse neoplasia and immunity: effects of radiation, hyperthermia, 2-deoxy-d-glucose, and Corynebacterium parvum. Oncology 1985, 42:391-398.
77. Grover G.J., Koetzner L., Wicks J., Gahler R.J., Lyon M.R., Reimer R.A., Wood S. Effects of the soluble fiber complex PolyGlycopleX on glucose homeostasis and body weight in young Zucker diabetic rats. Front. Pharmacol. 2011, (September):47.
78. Guerra G.P., Mello C.F., Bochi G.V., Pazini A.M., Fachinetto R., Dutra R.C., Calixto J.B., Ferreira J., Rubin M.A. Hippocampal PKA/CREB pathway is involved in the improvement of memory induced by spermidine in rats+. Neurobiol. Learn. Mem. 2011, 96:324-332.
79. Guerra G.P., Mello C.F., Bochi G.V., Pazini A.M., Rosa M.M., Ferreira J., Rubin M.A. Spermidine-induced improvement of memory involves a cross-talk between protein kinases C and A. J. Neurochem. 2012, 122:363-373.
80. Guevara-Aguirre J., Balasubramanian P., Guevara-Aguirre M., Wei M., Madia F., Cheng C.W., Hwang D., Martin-Montalvo A., Saavedra J., Ingles S., de Cabo R., Cohen P., Longo V.D. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci. Transl. Med. 2011, 3:70ra13.
81. Guo Z., Mattson M.P. In vivo 2-deoxyglucose administration preserves glucose and glutamate transport and mitochondrial function in cortical synaptic terminals after exposure to amyloid β-peptide and iron: evidence for a stress response. Exp. Neurol. 2000, 166:173-179.
82. Gupta V.K., Scheunemann L., Eisenberg T., Mertel S., Bhukel A., Koemans T.S., Kramer J.M., Liu K.S., Schroeder S., Stunnenberg H.G., Sinner F., Magnes C., Pieber T.R., Dipt S., Fiala A., Schenck A., Schwaerzel M., Madeo F., Sigrist S.J. Restoring polyamines protects from age-induced memory impairment in an autophagy-dependent manner. Nat. Neurosci. 2013, 16:1453-1460.
83. Gupta Y.K., Briyal S., Chaudhary G. Protective effect of trans-resveratrol against kainic acid-induced seizures and oxidative stress in rats. Pharmacol. Biochem. Behav. 2002, 71:245-249.
84. Halloran J., Hussong S.A., Burbank R., Podlutskaya N., Fischer K.E., Sloane L.B., Austad S.N., Strong R., Richardson A., Hart M.J., Galvan V. Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience 2012, 223:102-113.
85. Hands S.L., Proud C.G., Wyttenbach A. mTOR's role in ageing: protein synthesis or autophagy?. Aging (Milano) 2006, 20:586-597.
86. Harrison D.E., Strong R., Sharp Z.D., Nelson J.F., Astle C.M., Flurkey K., Nadon N.L., Wilkinson J.E., Frenkel K., Carter C.S., Pahor M., Javors M.A., Fernandez E., Miller R.A. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
87. Harrison D.E., Strong R., Allison D.B., Ames B.N., Astle C.M., Atamna H., Fernandez E., Flurkey K., Javors M.A., Nadon N.L., Nelson J.F., Pletcher S., Simpkins J.W., Smith D., Wilkinson J.E., Miller R.A. Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell 2014, 13:273-282.
88. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004, 18:1926-1945.
89. Heilbronn L.K., de Jonge L., Frisard M.I., DeLany J.P., Larson-Meyer D.E., Rood J., Nguyen T., Martin C.K., Volaufova J., Most M.M., Greenway F.L., Smith S.R., Deutsch W.A., Williamson D.A., Ravussin E. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. J. Am. Med. Assoc. 2006, 295:1539-1548. Pennington CALERIE Team.
90. Hoffmann E., Wald J., Lavu S., Roberts J., Beaumont C., Haddad J., Elliott P., Westphal C., Jacobson E. Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. Br. J. Clin. Pharmacol. 2013, 75:186-196.
91. Hooge D.M. Turkey pen trials with dietary mannan oligosaccharide: meta-analysis, 1993-2003. Int. J. Poultry Sci. 2004, 3:179-188.
92. Houde V.P., BrÛlé S., Festuccia W.T., Blanchard P.G., Bellmann K., Deshaies Y., Marette A. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 2010, 59:1338-1348.
93. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., Scherer B., Sinclair D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425:191-196.
94. Hubbard B.P., Gomes A.P., Dai H., Li J., Case A.W., Considine T., Riera T.V., Lee J.E., E S.Y., Lamming D.W., Pentelute B.L., Schuman E.R., Stevens L.A., Ling A.J., Armour S.M., Michan S., Zhao H., Jiang Y., Sweitzer S.M., Blum C.A., Disch J.S., Ng P.Y., Howitz K.T., Rolo A.P., Hamuro Y., Moss J., Perni R.B., Ellis J.L., Vlasuk G.P., Sinclair D.A. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 2013, 339:1216-1219.
95. Huffman D.M. Exercise as a calorie restriction mimetic: implications for improving healthy Aging and longevity. Interdiscip. Top. Gerontol. 2010, 37:157-174.
96. Hursting S.D., Lavigne J.A., Berrigan D., Perkins S.N., Barrett J.C. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu. Rev. Med. 2003, 54:131-152.
97. Ingram D.K., Anson R.M., de Cabo R., Mamczarz J., Zhu M., Mattison J., Lane M.A., Roth G.S. Development of calorie restriction mimetics as a prolongevity strategy. Ann. N.Y. Acad. Sci. 2004, 1019:412-423.
98. Ingram D.K., Zhu M., Mamczarz J., Zou S., Lane M.A., Roth G.S., de Cabo R. Calorie restriction mimetics: an emerging research field. Aging Cell 2006, 5:97-108.
99. Ingram D.K., Roth G.S. Glycolytic inhibition as a strategy for developing calorie restriction mimetics. Exp. Gerontol. 2011, 46:148-154.
100. Jacob S., Rabbia M., Meier M.K., Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes. Metab. 2009, 11:361-371.
101. Jagannath C., Bakhru P. Rapamycin-induced enhancement of vaccine efficacy in mice. Methods Mol. Biol. 2012, 821:295-303.
102. ®, to commonly consumed foods on glycemic response, glycemic index and GRIP: a simple and effective strategy for reducing post prandial blood glucose levels-a randomized, controlled trial. Nutr. J. 2010, 9:58.
103. Jones A.R., Porter K.E., Dobbie M.S. Renal and spermatozoal toxicity of alpha-bromohydrin, 3-bromolactate and 3-bromopyruvate. J. Appl. Toxicol. 1996, 16:57-63.
104. Jull A.B., Ni Mhurchu C., Bennett D.A., Dunshea-Mooij C.A., Rodgers A. Chitosan for overweight or obesity. Cochrane Database Syst. Rev. 2008, 3(July):CD003892.
105. Kalyvas A.V., Vlachos K., Abu-Amara M., Sampalis J.S., Glantzounis G. Bariatric surgery as metabolic surgery for diabetic patients. Curr. Pharm. Des. 2013, (Sep 12, Epub ahead of print).
106. Kang H.T., Hwang E.S. 2-Deoxyglucose: an anticancer and antiviral therapeutic, but not any more a low glucose mimetic. Life Sci. 2006, 78:1392-1399.
107. Kapahi P., Chen D., Rogers A.N., Katewa S.D., Li P.W., Thomas E.L., Kockel L. With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab 2010, 11:453-465.
108. Karuppagounder S.S., Pinto J.T., Xu H., Chen H.L., Beal M.F., Gibson G.E. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem. Int. 2009, 54:111-118.
109. Keithley J., Swanson B. Glucomannan and obesity: a critical review. Altern. Ther. Health Med. 2005, 11:30-34.
110. Khan M.M., Ahmad A., Ishrat T., Khan M.B., Hoda M.N., Khuwaja G., Raza S.S., Khan A., Javed H., Vaibhav K., Islam F. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res. 2010, 1328:139-151.
111. Kim D., Sarbassov D., Ali S., King J., Latek R., Erdjument-Bromage H., Tempst P., Sabatini D. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002, 110:163-175.
112. Kim D., Sarbassov D., Ali S., Latek R., Guntur K., Erdjument-Bromage H., Tempst P., Sabatini D. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell 2003, 11:895-904.
113. Kim J.H., Kang M.J., Choi H.N., Jeong S.M., Lee Y.M., Kim J.I. Quercetin attenuates fasting and postprandial hyperglycemia in animal models of diabetes mellitus. Nutr. Res. Pract. 2011, 5:107-111.
114. Kim H.S., Patel K., Muldoon-Jacobs K., Bisht K.S., Aykin-Burns N., Pennington J.D., van der Meer R., Nguyen P., Savage J., Owens K.M., Vassilopoulos A., Ozden O., Park S.H., Singh K.K., Abdulkadir S.A., Spitz D.R., Deng C.X., Gius D. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 2010, 17:41-52.
115. Kim Y.D., Park K.G., Lee Y.S., Kim D.K., Nedumaran B., Jang W.G., Cho W.J., Ha J., Lee I.K., Lee C.H., Choi H.S. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 2008, 57:306-314.
116. Kincaid B1, Bossy-Wetzel E. Forever young: SIRT3 a shield against mitochondrial meltdown, aging, and neurodegeneration. Front. Aging Neurosci. 2013, 5:48.
117. Kirkland J.L., Peterson C. Healthspan, translation, and new outcomes for animal studies of aging. J. Gerontol. A. Biol. Sci. Med. Sci. 2009, 64:209-212.
118. Kirpichnikov D., McFarlane S.I., Sowers J.R. Metformin: an update. Ann. Intern. Med. 2002, 137:25-33.
119. Ko Y.H., Pedersen P.L., Geschwind J.F. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett. 2001, 173:83-91.
120. Ko Y.H., Smith B.L., Wang Y., Pomper M.G., Rini D.A., Torbenson M.S., Hullihen J., Pedersen P.L. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem. Biophys. Res. Commun. 2004, 324:269-275.
121. Ko Y.H., Verhoeven H.A., Lee M.J., Corbin D.J., Vogl T.J., Pedersen P.L. A translational study "case report" on the small molecule "energy blocker" 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside. J. Bioenerg. Biomembr. 2012, 44:163-170.
122. Kopchick J.J., Kelder B., Gosney E.S., Berryman D.E. Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications. Mol. Cell. Endocrinol. 2014, 386:34-45.
123. Kumao T., Fujii S., Asakawa A., Takehara I., Fukuhara I. Effect of coffee drink containing mannooligosaccharides on total amount of excreted fat in healthy adults. J. Health Sci. 2006, 52:482-485.
124. Kume S., Uzu T., Kashiwagi A., Koya D. SIRT1, a calorie restriction mimetic, in a new therapeutic approach for type 2 diabetes mellitus and diabetic vascular complications. Endocr. Metab. Immune Disord. Drug Targets 2010, 10:16-24.
125. Lamming D.W., Ye L., Katajisto P., Goncalves M.D., Saitoh M., Stevens D.M., Davis J.G., Salmon A.B., Richardson A., Ahima R.S., Guertin D.A., Sabatini D.M., Baur J.A. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012, 335:1638-1643.
126. Lamming D.W., Ye L., Sabatini D.M., Baur J.A. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J. Clin. Invest. 2013, 123:980-989.
127. Lane M.A., Ingram D.K., Roth G.S. 2-Deoxy-d-glucose feeding in rats mimics physiological effects of calorie restriction. J. Anti Aging Med. 1998, 1:327-337.
128. LaRocca T.J., Gioscia-Ryan R.A., Hearon C.M., Seals D.R. The autophagy enhancer spermidine reverses arterial aging. Mech. Ageing Dev. 2013, 134:314-320.
129. Lavu S., Boss O., Elliott P.J., Lambert P.D. Sirtuins-novel therapeutic targets to treat age-associated diseases. Nat. Rev. Drug Discov. 2008, 7:841-853.
130. Lee J., Bruce-Keller A.J., Kruman Y., Chan S.L., Mattson M.P. 2-Deoxy-d-glucose protects hippocampal neurons against excitotoxic and oxidative injury: evidence for the involvement of stress proteins. J. Neurosci. Res. 1999, 57:48-61.
131. Leontieva O.V., Paszkiewicz G.M., Blagosklonny M.V. Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet. Aging Cell 2014, (Mar 22, Epub ahead of print). 10.1111/acel.12211.
132. Libri V., Brown A.P., Gambarota G., Haddad J., Shields G.S., Dawes H., Pinato D.J., Hoffman E., Elliot P.J., Vlasuk G.P., Jacobson E., Wilkins M.R., Matthews P.M. A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLOS ONE 2012, 7(12):e51395. (Dec 20, Epub). 10.1371/journal.pone.0051395.
133. Liu D., Pitta M., Jiang H., Lee J.H., Zhang G., Chen X., Kawamoto E.M., Mattson M.P. Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession. Neurobiol. Aging 2013, 34:1564-1580.
134. Longo V.D., Fontana L. Calorie restriction and cancer prevention: metabolic and molecular mechanisms. Trends Pharmacol. Sci. 2010, 31:89-98.
135. Lyon M.R., Reichert R.G. The effect of a novel viscous polysaccharide along with lifestyle changes on short-term weight loss and associated risk factors in overweight and obese adults: an observational retrospective clinical program analysis. Altern. Med. Rev. 2010, 15:68-75.
136. Madiraju A.K., Erion D.M., Rahimi Y., Zhang X.M., Braddock D.T., Albright R.A., Prigaro B.J., Wood J.L., Bhanot S., MacDonald M.J., Jurczak M.J., Camporez J.P., Lee H.Y., Cline G.W., Samuel V.T., Kibbey R.G., Shulman G.I. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014, 510:542-546.
137. Madsbad S., Dirksen C., Holst J.J. Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol. 2014, 2:152-164.
138. Majumder S., Caccamo A., Medina D.X., Benavides A.D., Javors M.A., Kraig E., Strong R., Richardson A., Oddo S. Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1β and enhancing NMDA signaling. Aging Cell 2012, 11:326-335.
139. Mamczarz J., Duffy K., Bowker J., Zhu M., Hagepanos A., Ingram D. Enhancement of amphetamine-induced locomotor response in rats on different regimens of diet restriction and 2-deoxyglucose treatment. Neuroscience 2005, 131:451-461.
140. Martin-Montalvo A., Mercken E.M., Mitchell S.J., Palacios H.H., Mote P.L., Scheibye-Knudsen M., Gomes A.P., Ward T.M., Minor R.K., Blouin M.J., Schwab M., Pollak M., Zhang Y., Yu Y., Becker K.G., Bohr V.A., Ingram D.K., Sinclair D.A., Wolf N.S., Spindler S.R., Bernier M., de Cabo R. Metformin improves healthspan and lifespan in mice. Nat. Commun. 2013, 4:2192.
141. Masoro E.J. Overview of caloric restriction and ageing. Mech. Ageing Dev. 2005, 126:913-922.
142. Mattison J.A., Roth G.S., Beasley T.M., Tilmont E.M., Handy A.M., Herbert R.L., Longo D.L., Allison D.B., Young J.E., Bryant M., Barnard D., Ward W.F., Qi W., Ingram D.K., de Cabo R. Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 2012, 489:318-321.
143. Mattison J.A., Wang M., Bernier M., Zhang J., Park S.S., Maudsley S., An S.S., Santhanam L., Martin B., Faulkner S., Morrell C., Baur J.A., Peshkin L., Sosnowska D., Csiszar A., Herbert R.L., Tilmont E.M., Ungvari Z., Pearson K.J., Lakatta E.G., de Cabo R. Resveratrol prevents high fat/sucrose diet-induced central arterial wall inflammation and stiffening in nonhuman primates. Cell Metab. 2014, 20:183-190.
144. Mattson M. Dietary factors, hormesis health. Ageing Res. Rev. 2008, 7:43-48.
145. Mendelsohn A.R., Larrick J.W. Fibroblast growth factor-21 is a promising dietary restriction mimetic. Rejuv. Res. 2012, 15:624-628.
146. Mercken E.M., Carboneau B.A., Krzysik-Walker S.M., de Cabo R. Of mice and men: the benefits of caloric restriction, exercise, and mimetics. Ageing Res. Rev. 2012, 11:390-398.
147. Mercken E.M., Mitchell S.J., Martin-Montalvo A., Minor R.K., Almeida M., Gomes A.P., Scheibye-Knudsen M., Palacios H.H., Licata J.J., Zhang Y., Becker K.G., Khraiwesh H., González-Reyes J.A., Villalba J.M., Baur J.A., Elliott P., Westphal C., Vlasuk G.P., Ellis J.L., Sinclair D.A., Bernier M., de Cabo R. SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass. Aging Cell 2014, 13:787-796.
148. Mhurchu C.N., Dunshea-Mooij C., Bennett D., Rodgers A. Effect of chitosan on weight loss in overweight and obese individuals: a systematic review of randomized controlled trials. Obes. Rev. 2005, 6:35-42.
149. Miller R.A., Harrison D.E., Astle C.M., Baur J.A., Boyd A.R., de Cabo R., Fernandez E., Flurkey K., Javors M.A., Nelson J.F., Orihuela C.J., Pletcher S., Sharp Z.D., Sinclair D., Starnes J.W., Wilkinson J.E., Nadon N.L., Strong R. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J. Gerontol. A. Biol. Sci. Med. Sci. 2011, 66:191-201.
150. Miller R.A., Harrison D.E., Astle C.M., Fernandez E., Flurkey K., Han M., Javors M.A., Li X., Nadon N.L., Nelson J.F., Pletcher S., Salmon A.B., Sharp Z.D., Van Roekel S., Winkleman L., Strong R. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell 2013, (December). 10.1111/acel.12194.
151. Miller R.A., Harrison D.E., Astle C.M., Floyd R.A., Flurkey K., Hensley K.L., Javors M.A., Leeuwenburgh C., Nelson J.F., Ongini E., Nadon N.L., Warner H.R., Strong R. An Aging Interventions Testing Program: study design and interim report. Aging Cell 2007, 6:565-575.
152. Milman S., Atzmon G., Huffman D.M., Wan J., Crandall J.P., Cohen P., Barzilai N. Low insulin-like growth factor-1 level predicts survival in humans with exceptional longevity. Aging Cell 2014, (Mar 12, Epub ahead of print). 10.1111/acel.12213.
153. Milne J.C., Lambert P.D., Schenk S., Carney D.P., Smith J.J., Gagne D.J., Jin L., Boss O., Perni R.B., Vu C.B., Bemis J.E., Xie R., Disch J.S., Ng P.Y., Nunes J.J., Lynch A.V., Yang H., Galonek H., Israelian K., Choy W., Iffland A., Lavu S., Medvedik O., Sinclair D.A., Olefsky J.M., Jirousek M.R., Elliott P.J., Westphal C.H. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450:712-716.
154. Minois N. Molecular basis of the 'anti-aging' effect of spermidine and other natural polyamines - a mini-review. Gerontology 2014, (Jan 28, Epub ahead of print).
155. Minois N., Carmona-Gutierrez D., Madeo F. Polyamines in aging and disease. Aging (Albany NY) 2011, 8:716-732.
156. Minor R.K., Baur J.A., Gomes A.P., Ward T.M., Csiszar A., Mercken E.M., Abdelmohsen K., Shin Y.K., Canto C., Scheibye-Knudsen M., Krawczyk M., Irusta P.M., Martín-Montalvo A., Hubbard B.P., Zhang Y., Lehrmann E., White A.A., Price N.L., Swindell W.R., Pearson K.J., Becker K.G., Bohr V.A., Gorospe M., Egan J.M., Talan M.I., Auwerx J., Westphal C.H., Ellis J.L., Ungvari Z., Vlasuk G.P., Elliott P.J., Sinclair D.A., de Cabo R. SRT1720 improves survival and healthspan of obese mice. Sci. Rep. 2011, 1:70.
157. Minor R.K., Smith D.L., Sossong A.M., Kaushik S., Poosala S., Spangler E.L., Roth G.S., Lane M., Allison D.B., de Cabo R., Ingram D.K., Mattison J.A. Chronic ingestion of 2-deoxy-d-glucose induces cardiac vacuolization and increases mortality in rats. Toxicol. Appl. Pharmacol. 2010, 243:332-339.
158. Miras A.D., le Roux C.W. Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?. Int. J. Obes. (Lond.) 2014, 38:325-333.
159. Mitchell S.J., Martin-Montalvo A., Mercken E.M., Palacios H.H., Ward T.M., Abulwerdi G., Minor R.K., Vlasuk G.P., Ellis J.L., Sinclair D.A., Dawson J., Allison D.B., Zhang Y., Becker K.G., Bernier M., de Cabo R. The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet. Cell Rep. 2014, 6:836-843.
160. Miyamura M., Schnell O., Yamashita C., Yoshioka T., Matsumoto C., Mori T., Ukimura A., Kitaura Y., Matsumura Y., Ishizaka N., Hayashi T. Effects of acarbose on the acceleration of postprandial hyperglycemia-induced pathological changes induced by intermittent hypoxia in lean mice. J. Pharm. Sci. 2010, 114:32-40.
161. Moore D.J., Yaser A., Connock M.J., Bayliss S. Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocr. Disord. 2009, 9:20.
162. Morselli E., Mariño G., Bennetzen M.V., Eisenberg T., Megalou E., Schroeder S., Cabrera S., Bénit P., Rustin P., Criollo A., Kepp O., Galluzzi L., Shen S., Malik S.A., Maiuri M.C., Horio Y., López-Otín C., Andersen J.S., Tavernarakis N., Madeo F., Kroemer G. Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. J. Cell Biol. 2011, 192:615-629.
163. + metabolism: a therapeutic target for age-related metabolic disease. Crit. Rev. Biochem. Mol. Biol. 2013, 48:397-408.
164. Nadon N.L., Strong R., Miller R.A., Nelson J., Javors M., Sharp Z.D., Peralba J.M., Harrison D.E. Design of aging intervention studies: the NIA interventions testing program. Age 2008, 30:187-199.
165. Neff F., Flores-Dominguez D., Ryan D.P., Horsch M., Schröder S., Adler T., Afonso L.C., Aguilar-Pimentel J.A., Becker L., Garrett L., Hans W., Hettich M.M., Holtmeier R., Hölter S.M., Moreth K., Prehn C., Puk O., Rácz I., Rathkolb B., Rozman J., Naton B., Ordemann R., Adamski J., Beckers J., Bekeredjian R., Busch D.H., Ehninger G., Graw J., Höfler H., Klingenspor M., Klopstock T., Ollert M., Stypmann J., Wolf E., Wurst W., Zimmer A., Fuchs H., Gailus-Durner V., Hrabe de Angelis M., Ehninger D. Rapamycin extends murine lifespan but has limited effects on aging. J. Clin. Invest. 2013, 123:3272-3291.
166. Nishimura K., Shiina R., Kashiwagi K., Igarashi K. Decrease in polyamines with aging and their ingestion from food and drink. J. Biochem. 2006, 139:81-90.
167. Omodei D., Fontana L. Calorie restriction and prevention of age-associated chronic disease. FEBS Lett. 2011, 585:1537-1542.
168. Onken B., Driscoll M. Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans healthspan via AMPK, LKB1, and SKN-1. PLoS ONE 2010, 5:e8758.
169. Onyango P., Celic I., McCaffery J.M., Boeke J.D., Feinberg A.P. SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13653-13658.
170. Ozcelik S., Fraser G., Castets P., Schaeffer V., Skachokova Z., Breu K., Clavaguera F., Sinnreich M., Kappos L., Goedert M., Tolnay M., Winkler D.T. Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. PLOS ONE 2013, 8(5):e62459.
171. Pacholec M., Bleasdale J.E., Chrunyk B., Cunningham D., Flynn D., Garofalo R.S., Griffith D., Griffor M., Loulakis P., Pabst B., Qiu X., Stockman B., Thanabal V., Varghese A., Ward J., Withka J., Ahn K. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 2010, 285:8340-8351.
172. Padwal R., Li S.K., Lau D.C. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int. J. Obes. Relat. Metab. Disord. 2003, 27:1437-1446.
173. Papanas N., Maltezos E. Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?. Curr. Pharm. Des. 2009, 15:3179-3192.
174. Park S.H., Ozden O., Jiang H., Cha Y.I., Pennington J.D., Aykin-Burns N., Spitz D.R., Gius D., Kim H.S. Sirt3, mitochondrial ROS, ageing, and carcinogenesis. Int. J. Mol. Sci. 2011, 12:6226-6239.
175. Park S.J., Ahmad F., Philp A., Baar K., Williams T., Luo H., Ke H., Rehmann H., Taussig R., Brown A.L., Kim M.K., Beaven M.A., Burgin A.B., Manganiello V., Chung J.H. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012, 148:421-433.
176. Parker J.C. Glucose-6-phosphate translocase as a target for the design of antidiabetic agents. Drugs Future 2001, 26:687.
177. Pearson K.J., Baur J.A., Lewis K.N., Peshkin L., Price N.L., Labinskyy N., Swindell W.R., Kamara D., Minor R.K., Perez E., Jamieson H.A., Zhang Y., Dunn S.R., Sharma K., Pleshko N., Woollett L.A., Csiszar A., Ikeno Y., Le Couteur D., Elliott P.J., Becker K.G., Navas P., Ingram D.K., Wolf N.S., Ungvari Z., Sinclair D.A., de Cabo R. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008, 8:157-168.
178. Pedersen P.L. Warburg, me and hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen. J. Bioenerg. Biomembr. 2007, 39:211-219.
179. Pilmore H.L. Metformin: potential benefits and use in chronic kidney disease. Nephrology 2010, 15:412-418.
180. Pucciarelli S., Moreschini B., Micozzi D., De Fronzo G.S., Carpi F.M., Polzonetti V., Vincenzetti S., Mignini F., Napolioni V. Spermidine and spermine are enriched in whole blood of nona/centenarians. Rejuv. Res. 2012, 15:590-595.
181. Ramirez R., Rasschaert J., Laghmich A., Louchami K., Nadi A.B., Jijakli H., Kadiata M.M., Sener A., Malaisse W.J. Uptake of d-mannoheptulose by normal and tumoral pancreatic islet cells. Int. J. Mol. Med. 2001, 7:631-638.
182. Rasschaert J., Kadiata M.M., Malaisse W.J. Effects of d-mannoheptulose upon d-glucose metabolism in tumoral pancreatic islet cells. Mol. Cell. Biochem. 2001, 226:77-81.
183. Rattan S.I.S. Hormesis in aging. Ageing Res. Rev. 2008, 7:63-78.
184. Reimer R.A., Grover G.J., Koetzner L., Gahler R.J., Lyon M.R., Wood S. The soluble fiber complex PolyGlycopleX lowers serum triglycerides and reduces hepatic steatosis in high-sucrose-fed rats. Nutr. Res. 2011, 31:296-301.
185. Ribaric G., Buchwald J.N., McGlennon T.W. Diabetes and weight in comparative studies of bariatric surgery vs. conventional medical therapy: a systematic review and meta-analysis. Obes. Surg. 2014, 24:437-455.
186. Ricci C., Gaeta M., Rausa E., Macchitella Y., Bonavina L. Early impact of bariatric surgery on type II diabetes, hypertension, and hyperlipidemia: a systematic review, meta-analysis and meta-regression on 6,587 patients. Obes. Surg. 2014, 24:522-528.
187. Richardson A. Rapamycin, anti-aging, and avoiding the fate of Tithonus. J. Clin. Invest. 2013, 123:3204-3206.
188. Roth G., Hayek M., Massimino S., Davenport G., Arking R., Bartke A., Bonkowski M., Ingram D. Mannoheptulose: glycolytic inhibitor and novel caloric restriction mimetic. Exp. Biol. 2009, (Abstract 553.1).
189. Roth G.S., Lane M.A., Ingram D.K. Caloric restriction mimetics: the next phase. Ann. N.Y. Acad. Sci. 2005, 1057:365-371.
190. Roth G.S., Lane M.A., Ingram D.K., Mattison J., Elahi D., Tobin J., Muller D., Metter E.J. Biomarkers of caloric restriction may predict longevity in humans. Science 2002, 297:881.
191. Rucker D., Padwal R., Li S.K., Curioni C., Lau D.C. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007, 335:1194-1199.
192. Sakata Y., Zhuang H., Kwansa H., Koehler R.C., Doré S. Resveratrol protects against experimental stroke: putative neuroprotective role of heme oxygenase 1. Exp. Neurol. 2010, 224:325-329.
193. Salminen A., Kaarniranta K. Regulation of the aging process by autophagy. Trends Mol. Med. 2009, 15:217-224.
194. Sarbassov D., Ali S., Kim D., Guertin D., Latek R., Erdjument-Bromage H., Tempst P., Sabatini D. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 2004, 14:1296-1302.
195. Scarpello J.H. Improving survival with metformin: the evidence base today. Diabetes Metab. 2003, 29. 6S36-6S43.
196. Schmeisser K., Mansfeld J., Kuhlow D., Weimer S., Priebe S., Heiland I., Birringer M., Groth M., Segref A., Kanfi Y., Price N.L., Schmeisser S., Schuster S., Pfeiffer A.F., Guthke R., Platzer M., Hoppe T., Cohen H.Y., Zarse K., Sinclair D.A., Ristow M. Role of sirtuins in lifespan regulation is linked to methylation of nicotinamide. Nat. Chem. Biol. 2013, 9:693-700.
197. Schmidt C. GSK/Sirtris compounds dogged by assay artifacts. Nat. Biotechnol. 2010, 28:185-186.
198. Schulz T.J., Zarse K., Voigt A., Urban N., Birringer M., Ristow M. Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress. Cell Metab. 2007, 6:280-293.
199. Selman C. Dietary restriction and the pursuit of effective mimetics. Proc. Nutr. Soc. 2014, (January):1-11.
200. Seyfried F., le Roux C.W., Bueter M. Lessons learned from gastric bypass operations in rats. Obes. Facts 2011, 4(Suppl. 1):3-12.
201. Sharma A.M., Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J. Hypertens. 2002, 20:1873-1878.
202. Siebenhofer A., Horvath K., Jeitler K., Berghold A., Stich A.K., Matyas E., Pignitter N., Siering U. Long-term effects of weight-reducing drugs in hypertensive patients. Cochrane Database Syst. Rev. 2009, 3(July):CD007654.
203. Sigrist S.J., Carmona-Gutierrez D., Gupta V.K., Bhukel A., Mertel S., Eisenberg T., Madeo F. Spermidine-triggered autophagy ameliorates memory during aging. Autophagy 2014, 10:178-179.
204. Sinclair D.A., Guarente L. Unlocking the secrets of longevity genes. Sci. Am. 2006, 294:48-57.
205. Slack C1, Foley A., Partridge L. Activation of AMPK by the putative dietary restriction mimetic metformin is insufficient to extend lifespan in Drosophila. PLOS ONE 2012, 7(10):e47699. 10.1371/journal.pone.0047699.
206. Smith D.L., Nagy T.R., Wilson L.S., Barnes S., Dong S., Allison D.B. The effect of mannan oligosaccharide supplementation on body weight gain and fat accrual in C57Bl/6J mice. Obesity 2010, 18:995-999.
207. Smith J.J., Kenney R.D., Gagne D.J., Frushour B.P., Ladd W., Galonek H.L., Israelian K., Song J., Razvadauskaite G., Lynch A.V., Carney D.P., Johnson R.J., Lavu S., Iffland A., Elliott P.J., Lambert P.D., Elliston K.O., Jirousek M.R., Milne J.C., Boss O. Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Syst. Biol. 2009, 10:31.
208. Soda K., Dobashi Y., Kano Y., Tsujinaka S., Konishi F. Polyamine-rich food decreases age-associated pathology and mortality in aged mice. Exp. Gerontol. 2009, 44:727-732.
209. ®, on satiety. Appetite 2014, 77C:74-78.
210. Someya S., Yu W., Hallows W.C., Xu J., Vann J.M., Leeuwenburgh C., Tanokura M., Denu J.M., Prolla T.A. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 2010, 143:802-812.
211. Sparks C.A., Guertin D.A. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010, 29:3733-3744.
212. Spilman P., Podlutskaya N., Hart M.J., Debnath J., Gorostiza O., Bredesen D., Richardson A., Strong R., Galvan V. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS ONE 2010, 5(April (4)):e9979.
213. Stanfel M.N., Shamieh L.S., Kaeberlein M., Kennedy B.K. The TOR pathway comes of age. Biochim. Biophys. Acta 2009, 1790:1067-1074.
214. Strong R., Miller R.A., Astle C.M., Floyd R.A., Flurkey K., Hensley K.L., Javors M.A., Leeuwenburgh C., Nelson J.F., Ongini E., Nadon N.L., Warner H.R., Harrison D.E. Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice. Aging Cell 2008, 7:641-650.
215. Strong R., Miller R.A., Astle C.M., Baur J.A., de Cabo R., Fernandez E., Guo W., Javors M., Kirkland J.L., Nelson J.F., Sinclair D.A., Teter B., Williams D., Zaveri N., Nadon N.L., Harrison D.E. Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span of genetically heterogeneous mice. J. Gerontol. A. Biol. Sci. Med. Sci. 2013, 68:6-16.
216. Takao I., Fujii S., Ishii A., et al. Effects of mannooligosaccharides from coffee mannan on fat storage in mice fed a high fat diet. J. Health Sci. 2006, 52:333-337.
217. Takahashi M., Inoue K., Yoshida M., Morikawa T., Shibutani M., Nishikawa A. Lack of chronic toxicity or carcinogenicity of dietary N-acetylglucosamine in F344 rats. Food Chem. Toxicol. 2009, 47:462-471.
218. Tatar M. Can we develop genetically tractable models to assess healthspan (rather than life span) in animal models?. J. Gerontol. A. Biol. Sci. Med. Sci. 2009, 64:209-212.
219. Tatar M., Bartke A., Antebi A. The endocrine regulation of aging by insulin-like signals. Science 2003, 299:1346-1355.
220. Timmers S., Konings E., Bilet L., Houtkooper R.H., van de Weijer T., Goossens G.H., Hoeks J., van der Krieken S., Ryu D., Kersten S., Moonen-Kornips E., Hesselink M.K., Kunz I., Schrauwen-Hinderling V.B., Blaak E.E., Auwerx J., Schrauwen P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011, 14(November (5)):612-622.
221. Tirupathi Pichiah P.B., Suriyakalaa U., Kamalakkannan S., Kokilavani P., Kalaiselvi S., SankarGanesh D., Gowri J., Archunan G., Cha Y.S., Achiraman S. Spermidine may decrease ER stress in pancreatic beta cells and may reduce apoptosis via activating AMPK dependent autophagy pathway. Med. Hypotheses 2011, 77:677-679.
222. Tokunaga C., Yoshino K., Yonezawa K. mTOR integrates amino acid- and energy-sensing pathways. Biochem. Biophys. Res. Commun. 2004, 313:443-446.
223. Tzatsos A., Kandror K.V. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol. Cell. Biol. 2006, 26:63-76.
224. Umemura M., Fujii S., Asano I., Hoshino H., Iino H. Effect of coffee mix drink containing mannooligosaccharides from coffee mannan on defecation and fecal microbiota in healthy volunteers. Food Sci. Technol. Res. 2004, 10:195-198.
225. Valenzano D.R., Terzibasi E., Genade T., Cattaneo A., Domenici L., Cellerino A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr. Biol. 2006, 16:296-300.
226. Venkatasubramanian S., Noh R.M., Daga S., Langrish J.P., Joshi N.V., Mills N.L., Hoffmann E., Jacobson E.W., Vlasuk G.P., Waterhouse B.R., Lang N.N., Newby D.E. Cardiovascular effects of a novel SIRT1 activator, SRT2104, in otherwise healthy cigarette smokers. J. Am. Heart Assoc. 2013, e000042. 10.1161/JAHA.113.000042.
227. Wan R., Camandola S., Mattson M.P. Intermittent fasting and dietary supplementation with 2-deoxy-d-glucose improve functional and metabolic cardiovascular risk factors in rats. FASEB J. 2003, 17:1133-1134.
228. Wan R., Camandola S., Mattson M.P. Dietary supplementation with 2-deoxy-d-glucose improves cardiovascular and neuroendocrine stress adaptation in rats. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H1186-H1193.
229. Wang X., Beugnet, Murakami M., Yamanaka, Proud C.G. Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins. Mol. Cell. Biol. 2005, 25:2558-2572.
230. Warburg O., Posener K., Negelein E. Ueber den Stoffwechsel der Tumoren. Biochem. Z. 1930, 152:319-344.
231. Weimer S., Priebs J., Kuhlow D., Groth M., Priebe S., Mansfeld J., Merry T.L., Dubuis S., Laube B., Pfeiffer A.F., Schulz T.J., Guthke R., Platzer M., Zamboni N., Zarse K., Ristow M. d-Glucosamine supplementation extends life span of nematodes and of ageing mice. Nat. Commun. 2014, 10.1038/ncomms4563.
232. Weindruch R., Keenan K.P., Carney J.M., Fernandes G., Feuers R.J., Floyd R.A., Halter J.B., Ramsey J.J., Richardson A., Roth G.S., Spindler S.R. Caloric restriction mimetics: metabolic interventions. J. Gerontol. A. Biol. Sci. Med. Sci. 2001, 56:20-33.
233. Weiss E.P., Racette S.B., Villareal D.T., Fontana L., Steger-May K., Schechtman K.B., Klein S., Holloszy J.O. Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial. Am. J. Clin. Nutr. 2006, 84:1033-1042. Washington University School of Medicine CALERIE Group.
234. Wilkinson J.E., Burmeister L., Brooks S.V., Chan C.C., Friedline S., Harrison D.E., Hejtmancik J.F., Nadon N., Strong R., Wood L.K., Woodward M.A., Miller R.A. Rapamycin slows aging in mice. Aging Cell 2012, 11:675-682.
235. Williams D.S., Cash A., Hamadani L., Diemer T. Oxaloacetate supplementation increases lifespan in Caenorhabditis elegans through an AMPK/FOXO-dependent pathway. Aging Cell 2009, 8:765-768.
236. Witte A.V., Kerti L., Margulies D.S., Flöel A. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J. Neurosci. 2014, 34:7862-7870.
237. Wood J.G., Rogina B., Lavu S., Howitz K., Helfand S.L., Tatar M., Sinclair D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004, 430:686-689.
238. Wu Z., Xu Q., Zhang L., Kong D., Ma R., Wang L. Protective effect of resveratrol against kainate-induced temporal lobe epilepsy in rats. Neurochem. Res. 2009, 34:1393-1400.
239. Xu R.H., Pelicano H., Zhou Y., Carew J.S., Feng L., Bhalla K.N., Keating M.J., Huang P. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 2005, 65:13-621.
240. Yamamoto H.A., Mohanan P.V. Effect of alpha-ketoglutarate and oxaloacetate on brain mitochondrial DNA damage and seizures induced by kainic acid in mice. Toxicol. Lett. 2003, 143:115-122.
241. Yamamoto M., Otsuki M. Effect of inhibition of alpha-glucosidase on age-related glucose intolerance and pancreatic atrophy in rats. Metabolism. 2006, 55:533-540.
242. Yamamoto T., Hinoi E., Fujita H., Iezaki T., Takahata Y., Takamori M., Yoneda Y. The natural polyamines spermidine and spermine prevent bone loss through preferential disruption of osteoclastic activation in ovariectomized mice. Br. J. Pharmacol. 2012, 166:1084-1096.
243. Yang D.L., Zhang H.G., Xu Y.L., Gao Y.H., Yang X.J., Hao X.Q., Li X.H. Resveratrol inhibits right ventricular hypertrophy induced by monocrotaline in rats. Clin. Exp. Pharmacol. Physiol. 2010, 37:150-155.
244. Yang Q., Inoki K., Ikenoue T., Guan K.L. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev. 2006, 20:2820-2832.
245. Yang W., Liu J., Shan Z., Tian H., Zhou Z., Ji Q., Weng J., Jia W., Lu J., Liu J., Xu Y., Yang Z., Chen W. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2014, 2:46-55.
246. Yao J., Chen S., Mao Z., Cadenas E., Brinton R.D. 2-Deoxy-d-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease. PLoS ONE 2011, 6(7):e21788. 10.1371/journal.pone.0021788.
247. Yip S., Plank L.D., Murphy R. Gastric bypass and sleeve gastrectomy for type 2 diabetes: a systematic review and meta-analysis of outcomes. Obes. Surg. 2013, 23:1994-2003.
248. Yoshikawa K. Studies on anti-diabetic effect of sodium oxaloacetate. Tohoku J. Exp. Med. 1968, 96:127-141.
249. Yoshino J., Conte C., Fontana L., Mittendorfer B., Imai S., Schechtman K.B., Gu C., Kunz I., Rossi Fanelli F., Patterson B.W., Klein S. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 2012, 16:658-664.
250. Yousuf S., Atif F., Ahmad M., Hoda N., Ishrat T., Khan B., Islam F. Resveratrol exerts its neuroprotective effect by modulating mitochondrial dysfunctions and associated cell death during cerebral ischemia. Brain Res. 2009, 1250:242-253.
251. Yu Z.F., Mattson M.P. Dietary restriction and 2-deoxyglucose administration reduce focal ischemic brain damage and improve behavioral outcome: evidence for a preconditioning mechanism. J. Neurosci. Res. 1999, 57:830-839.
252. Zemke D., Azhar S., Majid A. The mTOR pathway as a potential target for the development of therapies against neurological disease. Drug News Perspect. 2007, 20:495-499.
253. Zhang W., Kim D., Philip E., Miyan Z., Barykina I., Schmidt B., Stein H. The Gluco VIP study. A multinational, observational study to investigate the efficacy, safety and tolerability of acarbose as add-on or monotherapy in a range of patients: the Gluco VIP study. Clin Drug Invest. 2013, 33:263-274.
254. Zhang Y., Bokov A., Gelfond J., Soto V., Ikeno Y., Hubbard G., Diaz V., Sloane L., Maslin K., Treaster S., Réndon S., van Remmen H., Ward W., Javors M., Richardson A., Austad S.N., Fischer K. Rapamycin extends life and health in C57BL/6 mice. J. Gerontol. A. Biol. Sci. Med. Sci. 2014, 69:119-130.
255. Zhi J., Melia A.T., Eggers H., Joly R., Patel I.H. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J. Clin. Pharmacol. 1995, 35:1103-1108.
256. Zhou Y.H., Ma X.Q., Wu C., Lu J., Zhang S.S., Guo J., Wu S.Q., Ye X.F., Xu J.F., He J. Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. PLOS ONE 2012, 7:e39062.
257. Zhu Q., Tong Y., Wu T., Li J., Tong N. Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systematic meta-analysis. Clin. Ther. 2013, 35:880-899.
258. Zhu Z., Jiang W., McGinley J.N., Thompson H.J. 2-Deoxyglucose as an energy restriction mimetic agent: effects on mammary carcinogenesis and on mammary tumor cell growth in vitro. Cancer Res. 2005, 65:7023-7030.
259. Zlotnik A., Gruenbaum S.E., Artru A.A., Rozet I., Dubilet M., Tkachov S., Brotfain E., Klin Y., Shapira Y., Teichberg V.I. The neuroprotective effects of oxaloacetate in closed head injury in rats is mediated by its blood glutamate scavenging activity: evidence from the use of maleate. J. Neurosurg. Anesthesiol. 2009, 21:235-241.
260. Zlotnik A., Sinelnikov I., Gruenbaum B.F., Gruenbaum S.E., Dubilet M., Dubilet E., Leibowitz A., Ohayon S., Regev A., Boyko M., Shapira Y., Teichberg V.I. Effect of glutamate and blood glutamate scavengers oxaloacetate and pyruvate on neurological outcome and pathohistology of the hippocampus after traumatic brain injury in rats. Anesthesiology 2012, 116:73-83.
261. Zou S., Carey J.R., Liedo P., Ingram D.K., Müller H.G., Wang J.L., Yao F., Yu B., Zhou A. The prolongevity effect of resveratrol depends on dietary composition and calorie intake in a tephritid fruit fly. Exp. Gerontol. 2009, 44:472-476.